Nonsteroid Anti-Inflammatory Drugs Inhibit Both the Activity and the Inflammation-Induced Expression of Acid-Sensing Ion Channel

Total Page:16

File Type:pdf, Size:1020Kb

Nonsteroid Anti-Inflammatory Drugs Inhibit Both the Activity and the Inflammation-Induced Expression of Acid-Sensing Ion Channel The Journal of Neuroscience, October 15, 2001, 21(20):8026–8033 Nonsteroid Anti-Inflammatory Drugs Inhibit Both the Activity and the Inflammation-Induced Expression of Acid-Sensing Ion Channels in Nociceptors Nicolas Voilley, Jan de Weille, Julien Mamet, and Michel Lazdunski Institut de Pharmacologie Mole´ culaire et Cellulaire, Centre National de la Recherche Scientifique Unite´ , Mixte de Recherche 6097, Sophia Antipolis, 06560 Valbonne, France Nonsteroid anti-inflammatory drugs (NSAIDs) are major drugs neurons along with substance P and isolectin B4 and that, in against inflammation and pain. They are well known inhibitors case of inflammation, ASIC1a appears in some larger A␤ fibers, of cyclooxygenases (COXs). However, many studies indicate (2) that NSAIDs prevent the large increase of ASIC expression in that they may also act on other targets. Acidosis is observed in sensory neurons induced by inflammation, and (3) that NSAIDs inflammatory conditions such as chronic joint inflammation, in such as aspirin, diclofenac, and flurbiprofen directly inhibit tumors and after ischemia, and greatly contributes to pain and ASIC currents on sensory neurons and when cloned ASICs are hyperalgesia. Administration of NSAIDs reduces low-pH- heterologously expressed. These results suggest that the com- induced pain. The acid sensitivity of nociceptors is associated bined capacity to block COXs and inhibit both inflammation- with activation of H ϩ-gated ion channels. Several of these, induced expression and activity of ASICs present in nocicep- cloned recently, correspond to the acid-sensing ion channels tors is an important factor in the action of NSAIDs against pain. (ASICs) and others to the vanilloid receptor family. This paper Key words: acid-sensing ion channel; inflammation; dorsal shows (1) that ASIC mRNAs are present in many small sensory root ganglion; nociception; aspirin; NSAID Nonsteroid anti-inflammatory drugs (NSAIDs) have been gener- been identified and characterized: ASIC1a (Waldmann et al., ally considered as inhibitors of cyclooxygenases (COXs) (Walker, 1997a) and its splice variant ASIC1b (Chen et al., 1998), both 1995; Vane and Botting, 1998). Their anti-inflammatory and present in dorsal root ganglion (DRG) neurons; ASIC2a (Wald- analgesic action is thought to be mainly mediated via this inhibi- mann et al., 1996) and ASIC2b (Lingueglia et al., 1997), the latter tion. However, data have been accumulating through the years being the more abundant in DRGs and the former being only suggesting that NSAIDs also probably act on other targets to present in large DRG neurons (Garcia-An˜overos et al., 2001); counteract pain. One recent result in this regard is that COX-1- and ASIC3 (Waldmann et al., 1997b), abundant in peripheral and COX-2-deficient mice still show sensitivity to the analgesic sensory neurons and thought to mediate cardiac ischemic pain action of NSAIDs (Ballou et al., 2000). On the other hand, (Sutherland et al., 2001). This paper examines the relationships administration of NSAIDs reduces both cutaneous (Steen et al., between ASICs, nociceptors, and inflammatory pain and shows 1996) and corneal (Chen et al., 1997) pain induced by exposure to that NSAIDs inhibit the activity of this class of channels in a acidic pH in the absence of inflammation. COX-independent way, as well as their inflammation-induced Tissue acidosis is a dominant factor in inflammation and in expression. tumors and after ischemia (Reeh and Steen, 1996; Helmlinger et al., 1997) and has an important contribution in pain and hyper- MATERIALS AND METHODS algesia (Steen and Reeh, 1993; Steen et al., 1995). This is attrib- In situ hybridization. Sections (12 ␮m thick) of L4–L5 DRGs from normal utable to direct excitation of nociceptive sensory neurons by or inflamed adult rats were fixed and hybridized (15 hr at 52°C) in 12.5% ϩ formamide, 4ϫ SSC, 2.5ϫ Denhardt’s solution, 250 ␮g/ml herring sperm H -gated currents (Krishtal and Pidoplichko, 1981a; Bevan and DNA, 125 ␮g/ml yeast tRNA, and 5 ng/␮l oligonucleotides labeled with Yeats, 1991). Several channels corresponding to these currents biotin-21-dUTP by terminal transferase. For fluorescent labeling, detec- have been cloned recently and belong to the acid-sensing ion tion was performed with the ELF-97 mRNA In situ Hybridization kit channel (ASIC) family (Waldmann et al., 1996, 1997a,b; Lingue- (Molecular Probes, Eugene, OR) based on streptavidin–alkaline phos- phatase–biotinylated probe interaction and the substrate ELF-97, which glia et al., 1997; Chen et al., 1998) and to the vanilloid receptor yields green fluorescent precipitates. For diaminobenzidine labeling, family (Caterina et al., 1997; Tominaga et al., 1998) (for review, detection was performed with Dako (High Wycombe, UK) GenPoint see Kress and Zeilhofer, 1999). Different ASIC isoforms have with two cycles of amplification. Counterstain used hematoxylin. Probes were as follows: ASIC1a, CATTCTTGGAGACTTGGCTAAAGCG- GAAC; ASIC1b, GGGTCATCACTCTCATCCAGTCCTAGCAT; Received June 11, 2001; revised July 20, 2001; accepted July 26, 2001. ASIC2b, CCCAAACGGTCCATGAAGGCAGC; and ASIC3, CTGT- This work was supported by the Centre National de la Recherche Scientifique, the TCCAGAAATACCCCAGGAC. Results were confirmed with a second Association Franc¸aise contre les Myopathies, and the Association pour la Recherche set of probes. Control experiments were performed with ASIC1a sense sur le Cancer. We thank Dr. F. Kuper and Dr. A. Baron for fruitful discussion and M. Jodar and C. Widmann for expert technical assistance. oligonucleotide (CACAGATGGCTGATGAAAAGCAG), and back- Correspondence should be addressed to Prof. Michel Lazdunski, Institut de ground was assessed without probe. Each experiment was done on at Pharmacologie Mole´culaire et Cellulaire, Centre National de la Recherche Scien- least three animals. tifique Unite´ Mixte de Recherche 6097, 660 route des Lucioles, Sophia Antipolis, Substance P immunochemistry and isolectin B4 binding. After in situ 06560 Valbonne, France. E-mail: [email protected]. hybridization, slides were treated with anti-substance P (SP) antibody Copyright © 2001 Society for Neuroscience 0270-6474/01/218026-08$15.00/0 (dilution of 1:100; Sigma, St. Louis, MO) and revealed with anti-IgG Voilley et al. • NSAIDs Block the Activity and Expression of ASICs J. Neurosci., October 15, 2001, 21(20):8026–8033 8027 Texas Red-coupled antibodies (Jackson ImmunoResearch, West Grove, IB4-positive cells. Some SP-positive (40 Ϯ 8%) and IB4-positive PA). For isolectin B4 (IB4) binding, FITC-labeled IB4 was applied at (48 Ϯ 13%) cells do not express ASIC1a. ASIC3 is expressed in 12.5 ␮g/ml. IB4-positive cells appeared green, which was changed to red 50 Ϯ 7% of SP-positive and 43 Ϯ 9% of IB4-positive cells. Some with Adobe PhotoShop 5.0 (Adobe Systems, San Jose, CA) before Ϯ Ϯ superposition with ASIC-labeled pictures. Cell proportions and profiles SP-positive (48 13%) and IB4-positive (39 15%) cells do not were calculated by measuring individually and counting cells. express ASIC3. Similar labeling patterns were observed for Inflammation experiments. Right hindpaws of anesthetized male ASIC1b and for ASIC2b (data not shown), which are expressed in ␮ Wistar rats (7–9 weeks) were inflamed by a 50 l injection of complete SP- and IB4-positive and -negative neurons in the same propor- Freund’s adjuvant (Stein et al., 1988). L4–L5 DRGs were removed at day 2 on both sides, the left ganglia serving as negative controls. The tions as the other ASICs (i.e., 40–50%). anti-inflammatory drug was infused intraperitoneally when the injection In normal conditions, ASIC1a mRNA is mainly expressed in of adjuvant was given and was repeated the next day. The drugs used cells with cross-sectional areas between 200 and 600 ␮m 2 (mean were (in mg/kg): 8 diclofenac, 4 ibuprofen, 40 salicylate, 40 aspirin, 20 area, 522 Ϯ 36 ␮m 2) that correspond to cell diameters between 15 nimesulide, 8 nordihydroguaiaretic acid (NDGA), 0.1 dexamethasone ␮ (all from Sigma), 20 Zileuton (kindly provided by Abbott Labs, Irving, and 30 m (Fig. 1B). In inflammatory conditions, this area Ϯ ␮ 2 Ͻ TX), or 20 MK-886 (kindly provided by Merck-Frosst, Dorval, Quebec, increases significantly to 722 39 m ( p 0.001). This increase Canada). can be explained by the appearance of a population of ASIC1a- Reverse transcription-PCR experiments. Total RNA (2 ␮g) was reverse positive cells with areas of 600–1200 ␮m 2 (i.e., 30–40 ␮min transcripted (First-strand cDNA synthesis kit; Amersham Pharmacia diameter). The area of cells coexpressing the ASIC1a transcript Biotech, Arlington Heights, IL). One-twentieth was used per PCR con- Ϯ ␮ 2 dition. Primers used were (5Ј–3Ј, sense/antisense): ASIC1a (Waldmann and SP is increased from 514 47 m in normal conditions to 2 et al., 1997a), CACAGATGGCTGATGAAAAGCAG/CATGGTAA- 664 Ϯ 30 ␮m in inflamed conditions ( p Ͻ 0.006) and the number CAGCATTGCAGGTGC; ASIC1b (Chen et al., 1998), ATGCCGT- of coexpressing cells from 40 Ϯ 4to62Ϯ 7% ( p Ͻ 0.03). No GCGGTTGTCCC/same as ASIC1a; ASIC2a (Waldmann et al., 1996), difference in ASIC3 distribution has been observed between TCAACCTACAGATTCCCGACCCG/CGAGTCCCATCTCTGAGGAC- Ϯ ␮ 2 Ϯ ␮ 2 CGG; ASIC2b (Lingueglia et al., 1997), CTGCCTTCATGGAC- normal (705 43 m ) and inflammatory (653 33 m ) CGTTTG/same as ASIC2a; ASIC3 (Waldmann et al., 1997b), CCCA- conditions (Fig. 1B). There is no significant difference for GACCCAGACCCAGCCCTCC/CTGTTCCAGAAATACCCCAGGAC; ASIC1b (560 Ϯ 28 vs 556 Ϯ 33 ␮m 2) and ASIC2b (677 Ϯ 35 vs and ␤-actin (Nudel et al., 1983), GTGCCCATCTATGAGGGT- 729
Recommended publications
  • CELEBREX™ (Celecoxib Capsules)
    01/05/99 4:16 PM draft label 1 CELEBREX™ 2 (celecoxib capsules) 3 4 5 DESCRIPTION 6 7 CELEBREX (celecoxib) is chemically designated as 4-[5-(4-methylphenyl)-3- 8 (trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide and is a diaryl substituted 9 pyrazole. It has the following chemical structure: 10 O NH2 S O N N CF3 11 CH3 12 13 14 The empirical formula for celecoxib is C17H14F3N3O2S, and the molecular weight is 381.38. 15 16 CELEBREX oral capsules contain 100 mg and 200 mg of celecoxib. 17 18 The inactive ingredients in CELEBREX capsules include: croscarmellose sodium, edible 19 inks, gelatin, lactose monohydrate, magnesium stearate, povidone, sodium lauryl sulfate 20 and titanium dioxide. 21 22 CLINICAL PHARMACOLOGY 23 24 Mechanism of Action 25 CELEBREX is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, 26 analgesic, and antipyretic activities in animal models. The mechanism of action of 27 CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via 28 inhibition of cyclooxygenase-2 (COX-2), and at therapeutic concentrations in humans, 29 CELEBREX does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. 30 31 Pharmacokinetics 32 33 Absorption 34 Peak plasma levels of celecoxib occur approximately 3 hrs after an oral dose. Both peak 35 plasma levels (Cmax) and area under the curve (AUC) are roughly dose proportional 36 across the clinical dose range of 100-200 mg studied. At higher doses, under fasting 37 conditions, there is a less than proportional increase in Cmax and AUC which is thought 38 to be due to the low solubility of the drug in aqueous media.
    [Show full text]
  • Diclofenac Topical Patch Gel Solution Monograph
    Diclofenac Topical Patch, Gel and Solution National Drug Monograph March 2016 VHA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Action Diclofenac is the only nonsteroidal antiinflammatory drug (NSAID) approved in the U.S. for topical application. The mechanism of diclofenac is believed to be inhibition of prostaglandin synthesis, primarily by nonselectively inhibiting cyclooxygenase. The agents covered in this review are the four diclofenac topical products approved for analgesic purposes: Diclofenac epolamine / hydroxyethylpyrrolidine patch (DEHP) 1.3% approved in January 2007 Diclofenac sodium topical gel 1%, approved in October 2007 Diclofenac sodium topical solution 1.5% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in November 2009 Diclofenac sodium topical solution 2% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in January 2014 Indication(s) Under Review in this document (may include off Solution 1.5% Solution 2% label) Patch 1.3% Gel 1% (Drops) (MDP) Topical treatment Relief of the pain of Treatment of signs Treatment of the Also see Table 1 Product Descriptions of acute pain due osteoarthritis of joints and symptoms of pain of below. to minor strains, amenable to topical osteoarthritis of the osteoarthritis of sprains, and treatment, such as the knee(s) the knee(s) contusions knees and those of the hands.
    [Show full text]
  • Diclofenac Sodium Enteric-Coated Tablets) Tablets of 75 Mg Rx Only Prescribing Information
    ® Voltaren (diclofenac sodium enteric-coated tablets) Tablets of 75 mg Rx only Prescribing Information Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS.) • Voltaren® (diclofenac sodium enteric-coated tablets) is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS.) DESCRIPTION Voltaren® (diclofenac sodium enteric-coated tablets) is a benzene-acetic acid derivative. Voltaren is available as delayed-release (enteric-coated) tablets of 75 mg (light pink) for oral administration. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C14H10Cl2NNaO2, and it has the following structural formula The inactive ingredients in Voltaren include: hydroxypropyl methylcellulose, iron oxide, lactose, magnesium stearate, methacrylic acid copolymer, microcrystalline cellulose, polyethylene glycol, povidone, propylene glycol, sodium hydroxide, sodium starch glycolate, talc, titanium dioxide. CLINICAL PHARMACOLOGY Pharmacodynamics Voltaren® (diclofenac sodium enteric-coated tablets) is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Voltaren, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.
    [Show full text]
  • Arthritis Treatment Comparison Arthritis Treatment Comparison
    ARTHRITIS TREATMENT COMPARISON ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA CHELATING AGENTS Penicillamine Cap: 250mg ✓ (Cuprimine) Penicillamine Tab: 250mg ✓ (Depen) CYCLIC POLYPEPTIDE IMMUNOSUPPRESSANTS Cyclosporine Cap: 25mg, 100mg; ✓ (Gengraf, Neoral) Sol: 100mg/mL CYCLOOXYGENASE-2 INHIBITORS Celecoxib Cap: 50mg, 100mg, ✓ ✓ ✓ ✓ (Celebrex) 200mg, 400mg DIHYDROFOLIC ACID REDUCTASE INHIBITORS Methotrexate Inj: 25mg/mL; ✓ ✓ Tab: 2.5mg Methotrexate Tab: 5mg, 7.5mg, ✓ ✓ (Trexall) 10mg, 15mg INTERLEUKIN RECEPTOR ANTAGONISTS Anakinra Inj: 100mg/0.67mL ✓ (Kineret) Tocilizumab Inj: 20mg/mL, ✓ ✓ (Actemra) 162mg/0.9mL GOLD COMPOUNDS Auranofin Cap: 3mg ✓ (Ridaura) Gold sodium thiomalate Inj: 50mg/mL ✓ ✓ (Myochrysine) HYALURONAN AND DERIVATIVES Hyaluronan Inj: 30mg/2mL ✓ (Orthovisc) Sodium hyaluronate Inj: 1% ✓ (Euflexxa) Sodium hyaluronate Inj: 10mg/mL ✓ (Hyalgan) Sodium hyaluronate Inj: 2.5mL ✓ (Supartz) HYLAN POLYMERS Hylan G-F 20 Inj: 8mg/mL ✓ (Synvisc, Synvisc One) KINASE INHIBITORS Tofacitinib Tab: 5mg ✓ (Xeljanz) MONOCLONAL ANTIBODIES Ustekinumab Inj: 45mg/0.5mL, ✓ (Stelara) 90mg/mL MONOCLONAL ANTIBODIES/CD20-BLOCKERS Rituximab Inj: 100mg/10mL, ✓ (Rituxan) 500mg/50mL (Continued) ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA MONOCLONAL ANTIBODIES/TNF-BLOCKERS Adalimumab Inj: 20mg/0.4mL, ✓ ✓ ✓ ✓ (Humira) 40mg/0.8mL Golimumab Inj: 50mg/0.5mL, ✓ ✓ ✓ (Simponi) 100mg/mL Infliximab Inj: 100mg ✓ ✓ ✓ (Remicade) NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    [Show full text]
  • Efficacy of Ketoprofen Vs. Ibuprofen and Diclofenac: a Systematic Review of the Literature and Meta-Analysis P
    Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis P. Sarzi-Puttini1, F. Atzeni1, L. Lanata2, M. Bagnasco2 1Rheumatology Unit, L. Sacco University Hospital, Milan, Italy; 2Medical Department, Dompé SpA, Milan, Italy. Abstract Objective The aim of this systematic review of the literature and meta-analysis of randomised controlled trials (RCTs) was to compare the efficacy of orally administered ketoprofen with that of ibuprofen and/or diclofenac. Methods The literature was systematically reviewed in accordance with the Cochrane Collaboration guidelines. The search was restricted to randomised clinical trials published in the Medline and Embase databases up to June 2011, and comparing the efficacy of oral ketoprofen (50–200 mg/day) with ibuprofen (600-1800 mg/day) or diclofenac (75–150 mg/day). Results A total of 13 RCTs involving 898 patients met the inclusion criteria: eight comparing ketoprofen with ibuprofen, and five comparing ketoprofen with diclofenac. The results of the meta-analysis showed a statistically significant difference in efficacy in favour of ketoprofen. The difference between ketoprofen and the pooled ibuprofen/diclofenac data was also statistically significant (0.459, 95% CI 0.33-0.58; p=0.00) at all point-estimates of the mean weighted size effect. Ketoprofen was significantly superior to both diclofenac (mean = 0.422; 95% CI 0.19-0.65; p=0.0007) and ibuprofen (mean = 0.475; 95% CI 0.32-0.62; p=0.0000) at all point-estimates. Heterogeneity for the analysed efficacy outcome was not statisically significant in any of the meta-analyses. Conclusion The efficacy of orally administered ketoprofen in relieving moderate-severe pain and improving functional status and general condition was significantly better than that of ibuprofen and/or diclofenac.
    [Show full text]
  • Central Nervous System Toxicity of Mefenamic Acid
    Central Nervous System toxicity of mefenamic acid overdose compared to other NSAIDs: an analysis of cases reported to the United Kingdom National Poisons Information Service. Running header: CNS toxicity of mefenamic acid A Kamour1, S Crichton2, G Cooper3, DJ Lupton4, M Eddleston4,5, JA Vale6, JP Thompson 3, SHL Thomas1,7 1National Poisons Information Service, Newcastle Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Wolfson Unit, Claremont Place, Newcastle upon Tyne, NE2 4HH. 2Department of Primary Care and Public Health, King's College London, Capital House, London, SE1 3QD 3National Poisons Information Service, Cardiff Unit, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX. 4National Poisons Information Service, Edinburgh Unit, Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh EH16 4SA. 5Pharmacology, Toxicology and Therapeutics, University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. 6National Poisons Information Service, Birmingham Unit, City Hospital, Dudley Road, Birmingham B18 7QH. 7Medical Toxicology Centre, Institute of Cellular Medicine, Wolfson Building, Newcastle University, Newcastle NE2 4HH. Address for correspondence: Dr Ashraf Kamour, Acute Medical Unit, North Manchester General Hospital Delaunays Road, Crumpsall, Manchester, M8 5RB, UK. Tel: +44 (0)161 918 4673 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bcp.13169 This article is protected by copyright. All rights reserved. Fax: +44 (0)161 604 5323 Email: [email protected] Keywords: Mefenamic acid, non-steroidal anti-inflammatory drug, overdose, poisoning, CNS toxicity, convulsions.
    [Show full text]
  • Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac Or Ketorolac
    molecules Article Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac Héctor Isaac Rocha-González 1 , María Elena Sánchez-Mendoza 1, Leticia Cruz-Antonio 2, Francisco Javier Flores-Murrieta 1,3, Xochilt Itzel Cornelio-Huerta 1 and Jesús Arrieta 1,* 1 Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Colonia Casco de Santo Tomás, Miguel Hidalgo, Ciudad de México 11340, Mexico; [email protected] (H.I.R.-G.); [email protected] (M.E.S.-M.); fjfl[email protected] (F.J.F.-M.); [email protected] (X.I.C.-H.) 2 Facultad de Estudios Superiores Zaragoza, UNAM, Av. Guelatao No. 66, Colonia Ejército de Oriente, Iztapalapa, Ciudad de México 09230, Mexico; [email protected] 3 Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosió Villegas, Secretaría de Salud, Ciudad de México 14080, Mexico * Correspondence: [email protected]; Tel.: +55-5729-6300 (ext. 62740); Fax: +55-5622-5329 Received: 13 October 2020; Accepted: 31 October 2020; Published: 3 November 2020 Abstract: Although nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the main types of drugs used to treat pain, they have several adverse effects, and such effects can be reduced by combining two analgesic drugs. The aim of this study was to evaluate the nociceptive activity of methyleugenol combined with either diclofenac or ketorolac, and determine certain parameters of pharmacokinetics. For the isobolographic analysis, the experimental effective dose 30 (ED30) was calculated for the drugs applied individually. With these effective doses, the peak plasma concentration (Cmax) was found and the other parameters of pharmacokinetics were established.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • DICLOFENAC 25 Tablets
    New Zealand Datasheet 1 PRODUCT NAME DICLOFENAC 25 Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Diclofenac potassium tablets 25 mg 3 PHARMACEUTICAL FORM Each Diclofenac 25 tablet contains 25 mg of diclofenac potassium. The tablets are white to off- white, round, biconvex film-coated. The diameter is about 6.15 mm with a thickness of about 3.2 mm. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Diclofenac 25 tablets are indicated for the short-term treatment of the following acute conditions: • post-traumatic pain, inflammation and swelling, e.g. due to sprains; • post-operative pain, inflammation and swelling, e.g. following dental or orthopaedic surgery; • painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; • migraine attacks; • painful syndromes of the vertebral column; • non-articular rheumatism; • as an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. In keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. Fever alone is not an indication. Diclofenac should only be prescribed when the benefits are considered to outweigh the potential risks (see section 4.4). 4.2 Dose and method of administration After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used. Adults Following an initial loading dose of 50mg, 25-50mg is to be taken every eight hours if necessary. The maximum daily dose is 150mg. MIGRAINE An initial loading dose of 50mg, then if necessary a further 25-50mg after 2 hours. The maximum daily dose is 150mg.
    [Show full text]
  • Anti-Inflammatory Pain Powders Page: 1 of 5
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.26 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: June 20, 2013 Subject: Anti-Inflammatory Pain Powders Page: 1 of 5 Last Review Date: March 13, 2020 Anti-Inflammatory Pain Powders Description Celecoxib Powder, Diclofenac Powder, Fenoprofen Powder, Flurbiprofen Powder, Ibuprofen Powder, Ketoprofen Powder, Meloxicam Powder, Naproxen Powder, Tramadol Powder Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. Celecoxib, diclofenac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, meloxicam, and naproxen are non-steroidal anti-inflammatory drugs (NSAID) that decrease inflammation, pain and fever by inhibiting COX-1 and 2 enzymes, which then inhibit the production of prostaglandins and leukotrienes (1-7). Tramadol is a centrally acting synthetic opioid analgesic used to treat moderate to moderately severe chronic
    [Show full text]
  • VOLTAREN®-XR (Diclofenac Sodium Extended-Release) Tablets, USP Tablets 100 Mg Rx Only Prescribing Information
    VOLTAREN®-XR (diclofenac sodium extended-release) tablets, USP Tablets 100 mg Rx only Prescribing Information WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. (see WARNINGS.) VOLTAREN-XR is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS, WARNINGS). Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. (see WARNINGS.) DESCRIPTION VOLTAREN®-XR (diclofenac sodium extended-release) tablets, USP is a benzeneacetic acid derivative. VOLTAREN-XR is available as extended-release tablets of 100 mg (light pink) for oral administration. Diclofenac sodium is a white or slightly yellowish crystalline powder and is sparingly soluble in water at 25°C. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C14H10Cl2NNaO2, and it has the following structural formula The inactive ingredients in VOLTAREN-XR include: cetyl alcohol, hydroxypropyl methylcellulose, iron oxide, magnesium stearate, polyethylene glycol, polysorbate, povidone, silicon dioxide, sucrose, talc, titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action VOLTAREN®-XR has analgesic, anti-inflammatory, and antipyretic properties.
    [Show full text]
  • Diclofenac and Ibuprofen in Rheumatoid Arthritis and Osteoarthritis
    Diclofenac and Ibuprofen in Rheumatoid Arthritis and Osteoarthritis P. M. BROOKS, W. HILL and R. GEDDES Med. J. Aust, 1980, 1: 29-30. Forty patients with arthritis (26 rheumatoid and 14 osteoarthrosis) entered a five-week double-blind crossover trial of diclofenac and ibuprofen. Four patients failed to complete the 10-week trial. There was no statistically significant difference in parameters of disease activity for the rheumatoid arthritis patients, but patients with osteoarthrosis fared significantly better on diclofenac. There was a low incidence of side effects on both regimens. Diclofenac Sodium (Voltaren) is a non-steroidal non-pyrazole compound with anti- inflammatory, antipyretic and analgesic activity in laboratory animals.1 It has been shown to be well tolerated and effective in short-term therapy of degenerative joint disease2 and rheumatoid arthritis. To assess the place of diclofenac in clinical practice, we studied the effectiveness of this drug against ibuprofen in patients with rheumatoid arthritis and osteoarthrosis. METHODS A five-week double-blind crossover design was used, each patient receiving either Voltaren plus ibuprofen placebo or Voltaren placebo plus Ibuprofen, with treatments commencing in a random fashion. Diclofenac was presented as 25-mg enteric-coated tablets and ibuprofen was presented as 400-mg film-coated tablets. Treatment was commenced on a dose of 75 mg of diclofenac (one three times a day) or 1200 mg of ibuprofen : (one three times a day) and the dose was adjusted upwards if necessary at the end of weeks one and two. Patients then continued their dose for the three-week test period before changing over to the other medication.
    [Show full text]